Business Context and Reporting Period
Company: Viking Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 24, 2016
Event: Entry into a Material Definitive Agreement (Common Stock Purchase Agreement) with Aspire Capital Fund, LLC.
Key Financial Metrics and Transaction Details
- Total Commitment: Aspire Capital is committed to purchase up to $12.5 million of common stock over a 30-month term.
- Initial Transaction: 333,333 shares sold at $1.50 per share for an aggregate price of $500,000.
- Commitment Fee: 336,116 shares issued concurrently as consideration for entering the agreement.
- Use of Proceeds: Working capital and general corporate purposes.
- Financial Covenants: None. The agreement contains no financial or business covenants, restrictions on future financings, or penalties.
Material Changes and Pricing Mechanics
The filing details a new equity financing facility rather than a change in historical financial performance. Key pricing and structural terms include:
- Purchase Price: The lesser of (1) the lowest sale price on the purchase date, or (2) the arithmetic average of the three lowest closing sale prices during the ten consecutive business days preceding the purchase date.
- VWAP Option: If the closing price is above $0.40 and the company directs a purchase of at least 75,000 shares, it may issue a VWAP Purchase Notice for up to 30% of trading volume at 97% of the volume-weighted average price.
- Price Floor: No sales may occur if the closing sale price is less than $0.25.
- Control: The Company controls the timing and amount of sales; Aspire Capital has no right to require sales but is obligated to purchase as directed.
Guidance, Risks, and Contingencies
- Termination Rights: The Company may terminate the agreement at any time for any reason without liability. Aspire Capital may terminate only if an event of default exists.
- Short-Selling Restriction: Aspire Capital is prohibited from engaging in direct or indirect short-selling or hedging of the common stock during the term.
- Registration Rights: The Company agreed to file registration statements to register the Initial Shares, Commitment Shares, and future shares for sale under the Securities Act of 1933.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks and uncertainties that could cause actual results to differ from expectations.
Investor Verification Checklist
- Verify the current trading price of Viking Therapeutics common stock relative to the $0.25 price floor and $0.40 VWAP threshold.
- Review the dilution impact of the initial 333,333 shares and 336,116 commitment shares issued on August 24, 2016.
- Confirm the status of the Registration Statement required to allow Aspire Capital to resell the shares.
- Monitor future 8-K filings for Purchase Notices to track the actual drawdown of the $12.5 million commitment.
- Check the Company's cash position to assess the immediate need for the working capital proceeds.